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ABSTRACT 
 
BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) 
which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor 
sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of 
nine patients affected by hemophilia A (HA), with variable disease severity, bleeding 
phenotype and comorbidities, to underline our clinical practice on prophylaxis with a 
recently introduced standard hall-life recombinant Factor VIII. The current case series 
highlights how the current clinical management of hemophilia is able to personalize 
treatment in several specific conditions like concomitant illnesses with thrombotic risk and 
allergic reactions. 
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Introduction 
Hemophilia A (HA) is a congenital bleeding disorder resulting from absence or deficiency 
of clotting factor VIII (FVIII). The symptoms consist of more or less severe hemorrhages 
as a result of trauma, surgical procedures, or spontaneous bleedings. These most likely 
occur into the joints (hemarthrosis) leading over the long term to progressive and 
irreversible hemophilic arthropathy, but bleeding may also occur into muscles, soft tissues 
and other sites (e.g. central nervous system) with potentially life-threatening consequences 
and, not least, drastic impairment in the individual's quality of life (QoL) [1]. 
The severity of bleeding phenotype depends on the degree of FVIII deficiency, or rather 
on the residual amount of FVIII plasma concentration, which classifies the disease as mild 
(FVIII ranges between 6 and 40 IU/dL), moderate (FVIII from 1 to 5 IU/dL) and severe (FVIII 
<1 IU/dL) [1].  
The prevalence of HA is approximately 1:7,500 males. The severe forms are usually 
diagnosed during the first year of life due to abnormal subcutaneous hematomas or 
hemarthroses, which may occur after minor trauma, or spontaneously [2]. 
Current guidelines for the management of patients with severe HA recommend prophylaxis 
with intravenous (IV) administration of FVIII concentrates in order to prevent spontaneous 
hemarthroses, preserve healthy joints, reduce the incidence of hemophilic arthropathy and 
improve QoL [3-8]. In patients with severe hemophilia, the success of prophylaxis depends 
on the maintenance of values of FVIII above the threshold of 1 IU/dL, based on early 
observations that patients with moderate HA rarely bleed and experience chronic 
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arthropathy [9]. Prophylaxis regimen with standard half-life concentrates is based on intra-
venous infusion of 25-40 IU/kg FVIII concentrates two or three times per week on non-
consecutive days, or every other day, representing a serious burden that significantly 
impacts the patient’s QoL. Furthermore, more recent findings suggest that patients could 
benefit from regimens that increase the trough FVIII level activity above 1 IU/dL (e.g. 3 or 
5 IU/dL), to prevent breakthrough bleeding experienced sometimes despite a continuous 
prophylactic treatment [10,11]. This approach takes into consideration the heterogeneity of 
the disease due to patients' characteristics and needs, including age, physical activity and 
bleeding frequency.  
The recently introduced half-life extension technologies have allowed the development of 
a first generation of long-acting FVIII concentrates with improved circulating survival [12]. 
However, the half-life extension of such FVIII was not as efficient as initially expected. for 
example, rFVIII Fc fusion protein (rFVIII-Fc, Elocta®), the only extended half-life rFVIII 
currently reimbursed in Italy, requires the administration of routine prophylaxis at the 
dosage of 50 IU/kg every four days, with the possibility to adjust the dose (25-65 IU/kg at 
3-5 days’ intervals) based on patient response.  
 
1.1.1 BAY 81-8973 (KOVALTRY®), A MODERN rFVIII 
 
One of the most recently approved rFVIII is BAY 81-8973 (Kovaltry®, Bayer, Berkley, CA, 
USA), which represents the evolution of Bayer’s well-established rFVIII-FS (Kogenate® FS, 
Bayer, Berkley, CA, USA) [2,5,7,13-20]. Despite being produced in the same baby hamster 
cells, compared with its predecessor rFVIII-FS, BAY 81-8973 is produced by modernized 
manufacturing technologies which eliminate the use of human- and/or animal-derived raw 
materials from the manufacturing process (third generation replacement FVIII), decreasing 
the risk for anti-FVIII antibodies (inhibitors) development and yielding a better safety profile 
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[19]. Moreover, it is known that concentrates with a higher von Willenbrand factor (VWF) 
content are associated to lower inhibitor development. Although BAY 81-8973 does not 
contain VWF, the molecule's characteristics (consistent glycosylation and sulfation of 6 
tyrosine sites, which make it more similar to endogenous FVIII) increase its affinity for the 
patient's VWF compared to other rFVIII, which may prevent inhibitor development [8]. 
Regarding the manufacturing process, two other characteristics need to be underlined from 
a pharmacokinetic (PK) point of view. First, BAY 81-8973 is a full-length rFVIII presenting 
glycans shifted to higher branched structures and slightly higher sialylation, which 
contribute to an improved PK profile, including slower clearance, higher area under the 
curve (AUC), and longer half-life (t1/2, mean 13.8 vs 12 hours) [13,20,21]. Second, its 
characteristics are further enhanced by the presence in the cells of the gene for human 
heat shock protein 70 (HPS70), which is essential for proper protein folding and increases 
FVIII expression. Data from comparative studies have confirmed PK parameters for BAY 
89-8173 to be non-inferior to – and for some PK variables significantly better than – those 
for rFVIII-FS and another commercial unmodified rFVIII (antihemophilic factor 
(recombinant) plasma/albumin-free method, rAHF-PFM, Advate®) in terms of higher AUC, 
prolonged t1/2 and mean residence time (MRT) after IV injection, and slower clearance [8 
The safety and efficacy of BAY 81-8973 have been extensively studied in the LEOPOLD 
(Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) international 
clinical development program [20,21,22,23], encompassing three separate trial segments 
in patients affected by severe HA: LEOPOLD I (part A: PK profile; part B: safety and 
efficacy in prophylaxis; part C: hemostasis during surgery and extension), LEOPOLD II 
(randomization to: on demand, low and high dose prophylaxis) and LEOPOLD KIDS (part 
A: PK profile, safety and efficacy in prophylaxis in previously treated patients; part B: PK 
profile, safety and efficacy in prophylaxis in previously untreated patients and extension) 
[22,23]. 
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The LEOPOLD I and II enrolled over 120 adolescent and adult patients with HA (12 to 65, 
mean age 30 years) featuring a compromised and difficult to manage joint status, most 
with target joints (71% Leopold I and 89.9% Leopold II). Of note, in these two clinical trials 
BAY 81-8973 demonstrated to effectively prevent bleeding episodes with both a twice-
weekly and three-times-weekly dosing prophylactic regimen [8,20,23].  
Here we describe a retrospective case series of 9 patients affected by HA, with variable 
disease severity, bleeding phenotype and/or comorbid conditions, to outline our clinical 
practice on BAY 81-8973 prophylaxis. We believe it is important to stress how observed 
treatment outcome is often subject to individual PK response to FVIII, and requires dosing 
regimens to be adjusted according to variables such as age, joint status, activity index, 
bleeding phenotype, adherence and other biasing factors [23; 24].  
 
1.1.2 CASE PRESENTATIONS 
 
The cases presented describe 9 patients (males, mean ± SD age 48.9 ± 15.9 years) with 
HA and variable disease severity, different bleeding phenotype and different clinical history, 
as described in Table 1. Patients did not have a previous history of inhibitor. All patients 
received treatment at least with another FVIII concentrate before switching to BAY 81-8973. 
The switch to BAY 81-8973 was proposed by caring hematologist to attain better PK 
parameters and/or to improve patient clinical and functional outcomes (specifically, 
reduction in annual bleeding rate – ABR – and longer intra-infusion interval).  
PK profiles are summarized in Figure 1. Individual PK evaluations were performed by 
means of the advanced WinNonlin software and/or WAPPS calculator, except for one case. 
Joint health was evaluated by using the Hemophilia Joint Health Score (HJHS), the 
Petterson score or the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-
US) score, as appropriate. 
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The cases described herein are reported in accordance to the CARE guidelines, as 
applicable. All information collected has been handled confidentially and is presented in 
order to safeguard patient identity. All patients signed an informed consent. 
 
1.1.3Case 1: 54-year-old male labor worker, with severe HA not complicated by inhibitor 
development. The patient presented obesity, chronic HCV-related hepatitis treated with 
interferon and ribavirin, arterial hypertension, and diabetes. He received on-demand 
treatment with FVIII until the year 2000, when he then started secondary prophylaxis with 
rAHF-PFM 40 IU/kg three times per week, though with poor adherence. In 2007, he 
underwent left knee-replacement arthroplasty. In 2015, after recurrent joint bleeding 
episodes (ABR=3), worsening of hemophilic arthropathy (HJHS=25) and onset of chronic 
pain to his left ankle, the prophylactic regimen was potentiated to a dose of 40 IU/kg three 
times per week. In 2017, in view of switching to BAY 81-8973, a PK study was done to 
compare previous and current treatments. After an appropriate wash-out period, PK 
parameters were measured after IV administration of rAHF-PFM 40 IU/kg and BAY 81-
8973 50 IU/kg. As evidenced by WinNonlin analysis, BAY 81-8973 led to a significant 
improvement of main PK parameters: MRT 22.52 vs 6.72 hrs, clearance 0.01 vs 0.03 
dL/h/Kg and t1/2 15.99 vs 7.08 hrs, with a 1.2 IU/dL trough level 96 hrs post-BAY 81-8973 
infusion. As to BAY 81-8973, WAPPS showed a t1/2 of 18.25 hrs (95% CI 17.00-19.25) and 
a “time to” 1 IU/dL, 2 IU/dL and 5 IU/dL of 136, 108 and 79 hrs, respectively. Accordingly, 
from March 2017 the patient continued prophylaxis with BAY 81-8973 45 IU/kg twice a 
week.  
In June 2017, during endoscopic examination and transgastric biopsy, the patient was 
diagnosed a pancreatic malignancy and started for it chemotherapy in September 2017. 
The patient continued prophylaxis throughout chemotherapy and after, with no hemorrhage, 
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except for one episode of melena during the first cycle of chemotherapy linked to erosive 
gastritis. The patient is still under treatment for pancreatic carcinoma. 
 
1.1.4Case 2: 35-year-old male, employee, affected by severe HA diagnosed at the age of 
1 year. Since then, he was treated on-demand with plasmaderived FVIII (pdFVIII, 
Haemate-P®) with no evidence of inhibitor development. Over the years, he developed 
hemophilic arthropathy mostly of the knees (especially right one). In December 2016, the 
patient began to experience pain during walking and standing. A physical examination 
confirmed the presence of severe joint impairment with limited limb extension (10-90°). A 
radiographic assessment showed bone loss at the femur, with a Petterson score of 13 at 
the right knee and 10 at the left one. Hence, he agreed to secondary prophylaxis. The 
patient received pdFVIII treatment at the dose of 35 IU/kg every other day and underwent 
a program of functional physical rehabilitation. Upon reactivation of an infection by human 
cytomegalovirus contracted many years earlier, the patient received antiviral treatment 
which permanently eradicated the virus; however, during the first month of antiviral 
treatment the patient manifested severe allergic reaction to pdFVIII, characterized by a 
widespread itchy urticarial rash and hypotension, suggesting a reaction mediated by IgE 
plasma protein. Accordingly, prophylactic treatment was temporarily suspended. The 
previous pdFVIII treatment was replaced with BAY 81-8973 in consideration of its lack of 
human or animal-derived proteins. The first infusion was performed in hospital in the 
intensive care unit. The initial dose established was 40 IU/kg every other day, but it was 
later reduced to two infusions per week, based on the favorable PK parameters (the PK 
parameters were elaborated starting from the laboratory data using the common 
mathematical methods without the help of dedicated software, considering the classic 
pharmacokinetic models with one and two compartments with determination of 
concentration logarithm, intravascular and extravascular administration). 
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During the following months, the patient was closely monitored for inhibitor development, 
which, however, did not occur. Joint function improved, and Petterson score for the right 
and left knee decreased from 13 and 10 to 9 and 7, respectively. No adverse therapy-
related reactions were reported after this switch.  
 
1.1.5Case 3: 48-year-old male with moderate HA, diagnosed at age of 2 years, history of 
allergic reactions to pdFVIII. No signs of hemophilic arthropathy, but frequent hematomas 
of the lower limbs. Occasional sports activity. Until September 2014, he received hospital-
based treatment with rFVIII-FS. In November 2014, after repeated muscle hematomas 
(ABR 4) that required daily substitution therapy, the patient agreed to secondary 
prophylaxis with 50 IU/kg FVIII-FS twice a week, foreseeing the same in-hospital 
premedication procedure (initially with antihistamine and steroid, and then with 
antihistamine alone). After four months of prophylaxis, despite the benefits obtained in 
terms of reduction in bleeding frequency, the patient decided to interrupt his prophylaxis 
due to the burden of frequent infusions and in-hospital premedication. Two years later, in 
March 2017 the patient was proposed to switch to BAY 81-8973 and to try again 
prophylaxis, in virtue of the product's higher purity and lower risk of allergic reaction. The 
patient began prophylaxis with 50 IU/kg twice a week and was progressively able to 
abandon in-hospital premedication within two months from treatment initiation. The PK 
study on BAY 81-8973 yielded a t1/2 >12 h and return to baseline FVIII (4 IU/dL) after 72 h. 
 
1.1.6 Case 4: 25-year-old male, affected by severe HA; moderate physical activity (yoga). 
For many years he received prophylaxis with rFVIII-FS 30 IU/kg three times per week 
achieving ABR=0. FVIII trough levels resulted <1 IU/dL at 48 h after the last infusion, the 
patient was recommended to switch to BAY 81-8973 at the same dosing regimen. 
Following this switch, the FVIII recovery improved, and trough levels raised to 2 IU/dL.  
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1.1.7Case 5: 56-year-old man with mild/moderate HA. He received on-demand treatment 
due to a mild bleeding phenotype (ABR 0) and the absence of target joints. Upon medical 
examination, he was diagnosed with hypertension in December 2014. Due to unstable 
angina he underwent percutaneous coronary intervention. After surgery, the patient started 
antiplatelet therapy and secondary prophylaxis with rFVIII (Helixate®) at the dosage of 20 
IU/kg, three times per week. During later cardiologic assessments, he was diagnosed with 
stress ischemia, restenosis of the anterior interventricular artery (IVA) and right coronary 
and de novo stenosis of the proximal IVA. Accordingly, he underwent transluminal 
percutaneous coronary angioplasty with a drug-eluting stent (DES) on IVA and Drug-
eluting balloon (DEB) on the right coronary and prescribed dual antiplatelet therapy (DAPT, 
aspirin plus clopidogrel). To minimize the risk of bleeding due to DAPT in a patient with an 
underlying bleeding disorder, the PK profile was evaluated, and treatment was switched to 
prophylaxis with BAY 81-8973 at the dosage of 20 IU/kg, three times per week. Compliance 
to treatment was good and a first laboratory result confirmed FVIII trough levels of 7 IU/dL. 
A second PK evaluation repeated after several months showed a FVIII trough levels of12 
IU/dL, a 24 h half-life and return to baseline FVIII levels after approximately 96 hours. 
 
1.1.8 Case 6: 53-year-old male with moderate HA and a job requiring heavy works. In the 
past he was treated on-demand and later on secondary prophylaxis with rFVIII-FS at the 
dosage of 30 IU/kg, twice a week, attaining an ABR of 3-4, with bleeding mostly occurring 
at the elbows and ankles and a 6 IU/dL trough level. Following ultrasound examination and 
HEAD-US score confirming the presence of hemophilic arthropathy, the patient was 
switched to BAY 81-8973 25 IU/kg twice a week in attempt to provide him a better 
protection against bleeding episodes. The efficacy of the new treatment was evaluated by 
means of PK study, comparing rFVIII-FS 30 IU/kg to BAY 81-8973 25 IU/kg. PK parameters 
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for these two products were similar at 48 h, while FVIII at 72 hrs was higher for BAY 81-
8973, being 5.9 IU/dL. 
 
1.1.9 Case 7: 61-year-old with moderate HA. Treated for many years on-demand and later 
on secondary prophylaxis with rFVIII-FS 30 IU/kg twice a week, attaining an ABR of 2-3, 
with hemarthrosis of ankles and knees and a FVIII through level of 6 IU/dL. By ultrasound 
examination of joints with HEAD-US score calculation, hemophilic arthropathy was 
confirmed, the patient was switched to BAY 81-8973 at the dosage of 30 IU/kg twice a 
week in order to provide a better protection against bleeding episodes. The efficacy of the 
new treatment was evaluated by means of PK study, comparing 30 IU/kg of both rFVIII-FS 
and BAY 81-8973. PK parameters showed a slightly better performance in favor of rFVIII-
FS until 48 hrs post-infusion, but a FVIII at 96 hours after BAY 81-8973 of 5.9 IU/dL. 
 
1.1.10 Case 8: 17-year-old male with severe HA diagnosed at birth. At the age of 1 year, 
he started prophylaxis treatment with a non-specified rFVIII at the dose of 30 IU/kg per 
infusion, without inhibitor development. Between 2011 and 2015, he received rFVIII-FS at 
the dosage of 30 IU/kg three times per week, attaining an ABR=2, showing excellent 
adherence to therapy. without target joints. In 2015, he complained of osteoarticular pain 
in particular of the knees. X-ray and ultrasound examination showed the presence of 
diffuse synovial hypertrophy; for this reason, prophylaxis was intensified to every other day. 
In July 2017, treatment was switched to BAY 81-8973 30 IU/kg twice a week, attaining an 
ABR=0. Comparison of PK assessment showed FVIII levels of 43 IU/dL at 4 hrs, 9.7 IU/dL 
at 24 hrs and 0.1 IU/dL at 48 hrs with rFVIII-FS; however, after switch to BAY 81-8973, 
FVIII levels increased to 67.6 IU/dL at 4 hours, 8.4 IU/dL at 48 hours and 4.4 IU/dL at 72 
hours, once the steady state was reached. 
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1.1.11 Case 9: 28-year-old male with severe HA diagnosed within the first year of life. The 
patient had no history of inhibitors, under prophylaxis with rFVIII-FS 30 IU/kg three times 
per week. He switched to BAY 81-8973 30 IU/kg three times per week. PK parameters with 
rFVIII-FS showed FVIII levels of 23.9 IU/dL at 4 hours, 1.2 IU/dL at 48 hours and 0.4 IU/dL 
at 72 hours. After switch to BAY 81-8973, PK assessment showed FVIII levels of 34.4 
IU/dL at 4 hrs, 4.5 IU/dL at 48 hrs and 1.7 IU/dL at 72 hrs. 
 
DISCUSSION 
 
In the last years, the prognosis of HA has dramatically improved thanks to the access to 
prophylaxis and newer generations of rFVIII. Although prophylaxis cannot reverse 
established joint damage in patients with long-standing disease, it has shown to effectively 
stabilize FVIII activity enough to decrease the frequency of bleeding and slow progression 
of joint disease. Indeed, early intervention at young age is largely encouraged by guidelines. 
Compliance to prophylaxis infusion schedules is equally important, given that outcomes 
have shown to be influenced by the time spent below  Factor VIII trough levels, due to 
increased breakthrough bleeds and hemarthroses [9,24,25]. 
As broadly acknowledged, individual response to injected FVIII is variable, and patients 
under the same prophylaxis schedule may exhibit widely variable trough levels. 
Pharmacokinetic studies have found that the age of the patient influences FVIIII clearance 
and half-life, with aging patients showing reduced FVIII clearance and increased half-life 
[24,25]. Accordingly, age-dependent changes in FVIII half-life appear to also impact the 
FVIII dosing regimen (units per Kg of body weight) required to maintain a trough level 
throughout prophylaxis. Weight also appears to have a role in individual variability, 
suggesting weight-based dose adjustments in overweight and obese patients [24]. 
However, because clinical bleeding patterns may significantly differ in patients having 
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similar coagulation factor activity, in addition to individual PK data, dosing is further tailored 
following a multidimensional approach considering bleeding pattern (frequency of bleeding 
episodes, hemarthrosis, affected joints), clinical history (age at first bleeding; orthopedic 
and instrumental scores, concentrate consumption), clinical response to treatment, and 
patient's life-style or needs [24]. In fact, although treatment efficacy is generally measured 
by PK parameters and infusion frequency, it is also true that while one patient might prefer 
fewer weekly infusions, another may need higher trough levels to contrast subclinical 
traumas caused by physical or occupational activities [24].  
Currently, individualized adjustments to FVIII replacement regimens are more and more 
often established by use of dedicated software able to handle the complex aspects of PK, 
and with a much lower number of blood samples –and less inconvenience for the patient–
than needed applying traditional PK study methods [24]. This approach helps 
hematologists to establish the most effective dose for patient and to decide on extension 
of injection intervals, and foresee outcome more reliably. 
Kovaltry represents a valid option in terms of effectiveness and safety of prophylaxis. Its 
full-length unmodified rFVIII molecular structure has led to an improvement in patients' PK 
parameters, with a longer half-life and a reduced clearance, allows to reduce infusion rate 
(dosing as few as twice weekly).  Extended half-life (EHL) Factor VIII drugs are now 
becoming commercially available in several countries and they represent a valid option to 
reach higher, stable levels of coagulation Factor VIII with fewer (from twice to once weekly) 
infusions, however they are not all approved for patients aged<12 years and long-term 
data on their safety are not yet available.  BAY 81-8973 thus remains a valuable treatment 
option, allowing to define schedules based on individual patients, treatment history, and 
clinical presentation. 
2.1.1 Improved PK and ABR in different bleeding phenotypes 
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Variability in individual response to FVIII treatment between individuals can be observed 
among the cases presented. As expected, in persons presenting the same grade of 
disease, higher doses of FVIII were required in younger vs older patients, and in patients 
overweight vs. within normal weight range. 
Current dosing recommendations suggest FVIII doses ranged from 25 to 40 IU/Kg, yet 
slightly higher doses were needed to accommodate the patient's needs. The patient in 
case 1 featured high weight (case 1), severe HA, and ongoing anticancer treatment; the 
patient in case 3 was affected by moderate HA, but dosage of 50 IU/Kg allowed two 
infusions weekly (FVIII:c= 4% at 72 h). 
With specific reference to effectiveness in terms of PK parameters, in case n. 1 treatment 
with Kovaltry® yielded a threefold MRT, and a twofold t1/2. This improved PK profile 
reduced intermittent bleeding episodes, improving the patient's quality of life. 
An example of variability in bleeding phenotypes can be observed in the cases of the three 
young adults affected by severe HA (cases 4, 8, 9). All three patients had been on 
treatment with Kogenate® at the dosage of 30 IU/Kg, three times/week for several years: 
while a 25-year old patient had attained an ABR of 0, the 17 years old patient maintained 
an ABR of 2.  Treatment switch to BAY 81-8973 resulted in ABR of zero in all cases, even 
though with different FVIII:c levels after 48 hours (1%, 4.4%, and 4.5% respectively) [24].  
The benefits of a better PK profile are not only remarkable for patients with severe HA, but 
also for those with moderate HA (cases n. 5, 6, 7). Currently, a revaluation of the optimal 
trough levels is ongoing, this to set as goal not only bleeding episodes prevention, but also 
improvement of arthropathy and subclinical bleedings control. Ideally, patients with severe 
HA should be treated for prophylaxis to attain FVIII:c >15% but the goal could be too 
ambitious due to cost issues. 
 
2.1.1 Hemophilia management and cancer treatment 
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The management of hemophilic cancer patients is a quite new and relevant aspect of 
hemophilia care, this issue has been recently discussed in a multicenter Italian study by 
Taliaferro et al.[26] In the above reported study, authors noted that hemophiliac cancer 
patients do not usually receive antihaemorrhagic prophylaxis during treatment of the 
underlying cancer, and that patients with concomitant inhibitor are not usually referred to 
chemo or radiotherapy, suggesting the lack of a proper prophylactic treatment schedule in 
this subset of patient and the missed opportunity for a proper treatment of the underlying 
cancer. Accordingly, prior stabilization of FVIII activity through prophylaxis becomes crucial. 
This was the case 1 description, where stabilization facilitated HA management in the 
planning of surgical interventions and anticancer treatment. Treatment burden was also 
reduced, with fewer infusions for the patient, which is particularly relevant in the case of 
oncological patients already exposed to several physically demanding treatments. 
Of note, in the study by Tagliaferri et al, authors also reported a higher rate of virus-related 
cancers among patients with severe hemophilia and lower rates of non-virus-related 
cancers, which decreased with the increase of disease severity. Nowadays, FVIII 
production technologies have overcome the risks of infection and other safety concerns, 
which further facilitates long-term patient management.  
 
2.1.3 Cardiovascular disease 
 
Stabilization of FVIII activity has also a central role in the outcome of several diseases and 
chronic conditions ensuing with aging. Patients with hemophilia may have a lower 
cardiovascular mortality but they have the same high prevalence of subclinical 
atherosclerosis as the general population [27]. Nowadays, persons with hemophilia 
actually present the same risk of cardiovascular disease (CVD) as the healthy population. 
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Among all cardiovascular risk factors, hypertension is quite common in hemophilia, it not 
only increases the risk of cardiovascular (CV) diseases, but also the risk of intracerebral 
bleeding [27]. Moreover, as life expectancy among persons with HA is increasing, there is 
a growing need to monitor individuals also for CV risk. Indeed, as evidenced in case 5, 
another very relevant aspect was the possibility of modulating prophylaxis in patients 
receiving antiplatelet and anticoagulant treatments. FVIII activity must also be monitored 
over time in order to detect any change in PK/PD profile and adjust treatment accordingly. 
Also in this case, stabilization of FVIII activity allows better planning of surgical 
interventions and related therapeutic adjustments. 
 
2.1.4 Allergic reactions 
 
Just as relevant, BAY 81-8973 also features a better safety profile in terms of a reduced 
risk of allergic reactions triggered by the replacement treatment (cases 2 and 3). Available 
data on this issue are quite scant. Generally, allergic reactions are more common in 
hemophilia B and they rarely occur in HA patients treated with FVIII. Allergic reactions to 
FVIII replacement treatment have been previously described by a retrospective study [28] 
on patients treated with plasma derived-FVIII (pd-FVIII). Based on results of the anti-FVIII 
immunoglobulin profile, the reported allergic reactions were triggered by other proteins 
contained in pd-FVII, thus they were not directed against FVIII [28]. The differentiated 
immunogenicity for pdFVIII and rFVIII was further described by Lai et al, though the exact 
mechanisms are still to be defined [29].  
Importantly, the switch to BAY 81-8973 in our cases allowed to avoid the need for in-
hospital support to prophylaxis, which was an important aspect both for the two patients 
with severe and moderate HA, respectively.  Moreover, prophylaxis with BAY 81-8973 in 
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the described case 2, allowed the patient to partially recover joint function, as confirmed 
by the improved Petterson score.   
 
2.1.5 Conclusions 
 
Overall, the use of this the third-generation recombinant factor BAY 81-8973 allows to 
reduce infusion rate and tailor dose according to a multidimensional approach considering 
PK parameters, variability in bleeding phenotype, age, weight, and patient's lifestyle, 
allowing patients to attain improved joint function, and increase of quality of life. Benefits 
were evident both for severe and moderate HA. 
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         Table 1: Clinical and HA-related variables of evaluated patients 
 
Variables Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 
Age/sex 54/M 35/M 48/M 25/M 56/M 53/M 61/M 
Weight (Kg)  102 72  60  62  100 80 61  
 24 
Work and 
physical 
activity labor worker   employee labor worker student labor worker   Labor worker   
Age 
diagnosis (Yr) Infancy 1  2  1  unknown 27  15  
HA severity severe severe moderate severe mild/moderate moderate moderate 
Target joint knee, ankle left knee 
muscular 
bleeding inferior 
limbs none none 
ankles, 
elbows 
knees, ankle 
left 
orthopaedic 
evaluation HJHS=25 
Petterson 
13 R, 10 L HJHS=16 HJHS=2 all negative HEAD-US HEAD-US 
ABR 3 4 4 1 0 3-4 2-3 
Previous HA 
treatment 
rAHF-PFM 
Advate 
Pd-FVIII 
Haemate-p 
rFVIII-FS 
Kogenate 
rFVIII-FS 
Kogenate rFVIII Helixate 
rFVIII-FS 
Kogenate 
rFVIII-FS 
Kogenate 
Dose 
previous 
treatment  
(UI/Kg) 40  35  50 30 20 30 30 
Dose 
frequency 
(times/week) 3 eod twice 3 3 twice twice 
On demand/ 
prophylaxis 
on demand 
since 2000, 
then 
prophylaxis on demand prophylaxis prophylaxis prophylaxis prophylaxis prophylaxis 
Relevant 
clinical 
history 
Related HCV 
chronic 
hepatitis 
treated with 
interferon and 
ribavirin, 
hypertension, 
diabetes, 
obesity, left 
knee 
arthorplasty 
Severe 
allergic 
reaction to 
pdFVIII, 
hypotension 
Allergic reaction 
to pdFVIII 
Recent fall  
in FVIII 
CVD disease, 
PTCA in 
treatment with 
antiplatelet + 
anticoagulant none none 
Comorbiditie
s 
Pancreatic 
cancer 
HCV related 
hepatitis 
Hyper-
cholesterolemia none 
Hypertension, 
restenosis, 
proximal VAT 
stenosis, stress 
ischemia hypertension 
HCV 
negativized in 
2014 
Switch date 
to Kovaltry Mar 2017 Apr 2017 Mar 2017 Dec 2017 Sep 2017 May 2017 May 2017 
Dose 
Kovaltry 
(IU/Kg) 45  40  50 30 20 25 30 
Frequency 
Kovaltry 
(times/week) 2 
eod; then 
twice/week twice 3 3 twice twice 
Legend: HA:Haemophilia A, eod: every other day; HCV: Hepatitis C virus; n.a.: not applicable; PTCA: percutaneous transluminar coronary angioplasty;  
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